Lixisenatide, a Novel GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes

Journal Title: International Journal of Health Sciences and Research - Year 2017, Vol 7, Issue 6

Abstract

Diabetes mellitus (DM) is an important global public health problem. Despite availability of many antidiabetic drugs, the glycemic goals cannot be achieved and serious complications of diabetes continue to happen. The adverse effects associated with antidiabetic medications are another issue. Glucagon like peptide-1 (GLP-1) receptor agonists are novel class of drugs, used for the treatment of type 2 DM. Recently lixisenatide is approved by United States Food and Drug Administration (US FDA) for the treatment of type 2 diabetes as add-on drug. Lixisenatide exerts its actions by acting on GLP-1 receptors, resulting in increase in insulin secretion, decrease in glucagon release, delay in gastric emptying and induction of satiety. Lixisenatide has demonstrated its clinical efficacy as antidiabetic by lowering of glycated hemoglobin (HbA1C) levels and reduction in 2 h postprandial plasma glucose (PPG) levels when used alone. Lixisenatide also has exerted synergistic antidiabetic effects when administered with metformin, sulfonylureas, pioglitazone and basal insulin in terms of greater fall in HbA1C levels and better control of 2 h PPG. Lixisenatide has been found to be non-inferior to other GLP-1 receptor agonists in reducing HbA1C and 2 h PPG with favourable side effect profile. The lixisenatide is less costly and has lower incidence of hypoglycaemia compared to exenatide and liraglutide. Overall it may serve as good add-on treatment to the existing antidiabetic drugs.

Authors and Affiliations

Amol Khanapure

Keywords

Related Articles

A Study on Dietary and Physical Modification among Gestational Diabetes Mellitus Patients

Background: Changes in dietary pattern and sedentary lifestyle increases the risk of Gestational Diabetes Mellitus that affect the fetal outcome and also increase the chances of developing type 2 diabetes mellitus in lat...

Childhood Intussusception: A 7 Years Prospective Analysis of Data in a Single Center

Background: Intussusception remains a common cause of bowel obstruction in children and results in significant morbidity and mortality if not promptly treated. There is a paucity of prospective studies regarding childhoo...

Spatial Pattern of Health and Health Care Facilities in District Anantnag of South Kashmir (J&K, India) -A Geo Medical Analysis

The main objective of this paper is to evaluate the spatial pattern of health and health care facilities in district Anantnag. The study was carried out across five altitudinal zones among different medical blocks in GIS...

Pulmonary Renal Syndrome: Update Article

The pulmonary–renal syndrome (PRS) refers to the combination of diffuse alveolar haemorrhage and rapidly progressive glomerulonephritis (RPGN). Pulmonary-renal syndrome can originate from various systemic autoimmune dise...

A Study of the Peripheral Smears in a Tertiary Care Teaching Hospital of Andaman & Nicobar Islands

Background: Peripheral blood film is one of the basic and highly informative haematological tool for screening, diagnosis and monitoring of disease progression and to look for therapeutic response. The understanding of p...

Download PDF file
  • EP ID EP370311
  • DOI -
  • Views 60
  • Downloads 0

How To Cite

Amol Khanapure (2017). Lixisenatide, a Novel GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes. International Journal of Health Sciences and Research, 7(6), 309-314. https://www.europub.co.uk/articles/-A-370311